Liraglutide (Saxenda for obesity, Victoza for T2D) was the first GLP-1 agonist approved for weight management. SCALE trials showed ~5-8% body-weight reduction at 56 weeks — modest by Tirzepatide / Semaglutide standards but meaningful pre-2017. Daily injection, less convenient than weekly Sema/Tirz. Generic versions filing post-2024 patent expiry.
Liraglutide
Monograph · ALiraglutide
Long-acting GLP-1 receptor agonist. Daily injection. Predecessor to semaglutide in the Novo Nordisk GLP-1 lineage.
How it clearsHalf cleared in ~13h. Most (~96%) gone by ~3d.

FDA-approved as Saxenda (obesity) and Victoza (T2D). Demonstrates 5-8% weight reduction at 56 weeks in SCALE trials — superseded by semaglutide and tirzepatide for newer use, but remains a covered option for many insurance formularies.
Cohort curves show movement — your n=1 often lags the median by one check-in cycle. The gap between "I should feel it" and "labs show it" is where most people quit early. Metabolic compounds still need lifestyle structure; modest results without it are mechanism, not failure.
Daily injection burden vs. weekly semaglutide is real. Same pancreatitis / gallbladder watch. Often used now as bridge while waiting for semaglutide / tirzepatide insurance approval.
C16 palmitoyl group conjugated at K20 via γ-glutamic acid spacer.
Known risk or pharmacological conflict.
Upload your data to see how it relates to Liraglutide.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyStack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Liraglutide remains useful when insurance won't cover Wegovy/Zepbound or when patients can't tolerate weekly dosing. With generics arriving, cash-pay cost drops materially. Daily injection is the friction point most users dislike — adherence drops noticeably vs weekly options.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- AStrong evidence
Liraglutide reduces body weight in SCALE and related RCTs
1 supporting referencesVerified 23d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
FDA approved (Saxenda / Victoza)
COFEPRIS issues counterfeit-Ozempic warning amid cross-border GLP-1 demand
COFEPRIS issued formal warnings about counterfeit Ozempic, Wegovy, and Saxenda circulating in Mexican gray markets, particularly in border-state pharmacies catering to US cross-border traffic. Several seizures documented in Tijuana, Juárez, and Reynosa.
Mexico (COFEPRIS) maintains GLP-1 prescription regime through obesity epidemic
COFEPRIS (Mexican federal health regulator) continued to require physician prescription for GLP-1 agonists through 2023-2024 despite high obesity prevalence and pharmacy-tourism demand from US patients. Compounding less restrictive than US 503A regime.
Pre-filled with this compound's published dose range: 0.6-3 mg · daily, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Saxenda (obesity) and Victoza (T2D). Generics filed; pricing dropping. Daily injection, less convenient than weekly Sema/Tirz.
As of 2026-04Saxenda + Victoza available COFEPRIS-registered MX pharmacies.
As of 2026-04No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.